Logo image of GLTO

GALECTO INC (GLTO) Stock Fundamental Analysis

NASDAQ:GLTO - Nasdaq - US36322Q2066 - Common Stock - Currency: USD

2.43  +0.05 (+2.1%)

Fundamental Rating

2

GLTO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for GLTO as it has an excellent financial health rating, but there are worries on the profitability. GLTO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GLTO has reported negative net income.
GLTO had a negative operating cash flow in the past year.
GLTO had negative earnings in each of the past 5 years.
GLTO had a negative operating cash flow in each of the past 5 years.
GLTO Yearly Net Income VS EBIT VS OCF VS FCFGLTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of GLTO (-125.14%) is worse than 80.63% of its industry peers.
The Return On Equity of GLTO (-135.42%) is worse than 61.44% of its industry peers.
Industry RankSector Rank
ROA -125.14%
ROE -135.42%
ROIC N/A
ROA(3y)-103.21%
ROA(5y)-74.46%
ROE(3y)-117.92%
ROE(5y)-83.79%
ROIC(3y)N/A
ROIC(5y)N/A
GLTO Yearly ROA, ROE, ROICGLTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

GLTO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLTO Yearly Profit, Operating, Gross MarginsGLTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for GLTO has been increased compared to 1 year ago.
GLTO has less shares outstanding than it did 5 years ago.
There is no outstanding debt for GLTO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GLTO Yearly Shares OutstandingGLTO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
GLTO Yearly Total Debt VS Total AssetsGLTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

GLTO has an Altman-Z score of -23.36. This is a bad value and indicates that GLTO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -23.36, GLTO is doing worse than 87.85% of the companies in the same industry.
There is no outstanding debt for GLTO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.36
ROIC/WACCN/A
WACCN/A
GLTO Yearly LT Debt VS Equity VS FCFGLTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

GLTO has a Current Ratio of 14.07. This indicates that GLTO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of GLTO (14.07) is better than 88.38% of its industry peers.
A Quick Ratio of 14.07 indicates that GLTO has no problem at all paying its short term obligations.
GLTO's Quick ratio of 14.07 is amongst the best of the industry. GLTO outperforms 88.56% of its industry peers.
Industry RankSector Rank
Current Ratio 14.07
Quick Ratio 14.07
GLTO Yearly Current Assets VS Current LiabilitesGLTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

GLTO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.73%, which is quite impressive.
EPS 1Y (TTM)51.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GLTO will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.23% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.06%
EPS Next 2Y-6.16%
EPS Next 3Y-20.18%
EPS Next 5Y15.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLTO Yearly Revenue VS EstimatesGLTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2030 10M 20M 30M
GLTO Yearly EPS VS EstimatesGLTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GLTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLTO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLTO Price Earnings VS Forward Price EarningsGLTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLTO Per share dataGLTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 -15

4.3 Compensation for Growth

GLTO's earnings are expected to decrease with -20.18% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.16%
EPS Next 3Y-20.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GLTO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALECTO INC

NASDAQ:GLTO (4/17/2025, 8:25:00 PM)

2.43

+0.05 (+2.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19 2025-03-19/amc
Earnings (Next)04-28 2025-04-28
Inst Owners13.05%
Inst Owner Change0%
Ins Owners3.61%
Ins Owner Change0.1%
Market Cap3.21M
Analysts82.5
Price Target8.16 (235.8%)
Short Float %1.44%
Short Ratio1.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-26.84%
Min EPS beat(2)-72.64%
Max EPS beat(2)18.96%
EPS beat(4)3
Avg EPS beat(4)12.17%
Min EPS beat(4)-72.64%
Max EPS beat(4)52.18%
EPS beat(8)7
Avg EPS beat(8)20.15%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-7.09%
EPS NY rev (3m)23.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.2
P/tB 0.2
EV/EBITDA N/A
EPS(TTM)-17.62
EYN/A
EPS(NY)-14.79
Fwd EYN/A
FCF(TTM)-14.11
FCFYN/A
OCF(TTM)-14.11
OCFYN/A
SpS0
BVpS11.99
TBVpS11.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -125.14%
ROE -135.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.21%
ROA(5y)-74.46%
ROE(3y)-117.92%
ROE(5y)-83.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.07
Quick Ratio 14.07
Altman-Z -23.36
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.83%
EPS Next Y16.06%
EPS Next 2Y-6.16%
EPS Next 3Y-20.18%
EPS Next 5Y15.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y53.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-223.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.55%
OCF growth 3YN/A
OCF growth 5YN/A